SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
February 10, 2004
------------------------------------------------
Date of Report (date of earliest event reported)
Zynex Medical Holdings, Inc.
----------------------------------------------------
Exact Name of Registrant as Specified in its Charter
Nevada 33-26787-D 87-0403828
- --------------------------- --------------- ----------------------
State or Other Jurisdiction Commission File IRS Employer Identifi-
of Incorporation Number cation Number
8100 South Park Way, Suite A-9
Littleton, Colorado 80120
----------------------------------------------------
Address of Principal Executive Offices Zip Code
(303) 703-4906
------------------------------
Registrant's Telephone Number,
Including Area Code
378 North Main, No. 124, Logan, Utah 84041
-------------------------------------------
Former Name or Former Address, if Changed
Since Last Report
ITEM 4. CHANGE IN REGISTRANT'S CERTIFYING ACCOUNTANT
On February 10, 2004, we were notified by Bierwolf, Nilson & Associates,
that due to partner rotation requirements of the Sarbannes-Oxley Act, the
accounting firm would be merging with a Salt Lake City, Utah firm, Chisholm &
Associates. The name of the new accounting firm will be Chisholm, Bierwolf &
Nilson, LLC.
The reports of Zynex Medical Holdings, Inc., on the financial statements
as of and for the fiscal year ended September 30, 2003, did not contain an
adverse opinion or disclaimer of opinion and was not qualified or modified as
to uncertainty, audit scope, or accounting principles, except that Bierwolf,
Nilson & Associates issued an explanatory paragraph in its fiscal 2003 and
2002 reports as to Zynex Medical Holdings, Inc. ability to continue as a going
concern.
During the years ended September 30, 2003 and 2002 and through the date
of this Current Report on Form 8-K, there were no disagreements with Bierwolf,
Nilson & Associates on any matter of accounting principles or practices,
financial statement disclosure, or auditing scope or procedure, which if not
resolved to Chisholm, Bierwolf & Nilson LLC's satisfaction, would have caused
it to make reference to the subject matter in connection with its report on
the Registrant's consolidated financial statements for such years; and there
were no reportable events as defined in Item 304(a)(1)(iv)(B) of Regulation
S-B.
On February 10, 2004, the Company engaged Chisholm, Bierwolf & Nilson,
LLC, to review its financial statements for the periods ending December 31,
2003. During the two most recent fiscal years and through the date of this
report, the Company has not consulted with Chisholm, Bierwolf & Nilson, LLC
regarding (i) the application of accounting principles to a specified
transaction, either completed or proposed, or the type of audit opinion that
might be rendered on the Company's financial statements, and no written report
or oral advice was provided to the Company by concluding there was an
important factor to be considered by the Company in reaching a decision as to
an accounting, auditing or financial reporting issue; or (ii) any matter was
either the subject of a disagreement, as that term is defined in Item
304(a)(1)(iv) of Regulation S-K and the related instructions thereto, or a
reportable event, as that term is defined in Item 304(a)(1)(v) of Regulation
S-K.
Zynex Medical Holdings, Inc., has provided a copy of this disclosure to
Bierwolf, Nilson & Associates in compliance with the provisions of Item 304
(a)(3) of Regulation S-B. See Exhibit 16.1 Letter from Accountant's Firm to
the Securities and Exchange Commission dated March 1, 2004.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(c) Exhibits
Exhibit 16 Letter from Bierwolf, Nilson & Associates
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf by the
undersigned, hereunto duly authorized.
ZYNEX MEDICAL HOLDINGS, INC.
Dated: March 2, 2004 By:/s/ Thomas Sandgaard
Thomas Sandgaard, President
3